Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
UCN-01 (7-hydroxy-staurosporine) is a potent and selective inhibitor of protein kinase C (PKC), one of several protein kinases examined. UCN-01 itself was shown to exhibit antitumor activity in vitro and in vivo in oncogene-activated human and murine tumor cell lines. Since the mechanism(s) of action of UCN-01 is thought to be different from those of alkylating agents, including mitomycin C (MMC), we tested the combined effect of UCN-01 with MMC on human epidermoid carcinoma A431 cells. UCN-01 potentiated the antiproliferative activity of MMC and yet it did not affect the growth of the cells in vitro. However, other nonselective protein kinase inhibitors, such as staurosporine, K-252a, KT6124 (a derivative of K-252a) and H7, did not enhance the activity of MMC. Isobologram analysis revealed that the interaction of UCN-01 with MMC was synergistic in its antiproliferative activity. A DNA histogram of A431 cells treated with both UCN-01 and MMC showed a block in the cell cycle at the G1/S phase. However, a histogram of cells treated with UCN-01 or MMC alone showed a G1 or a G2M block, respectively. The combined effect of UCN-01 with MMC was further examined in vivo in xenografted A431 cells in nude mice. The combination of both drugs in a single i.v. injection exhibited greater antitumor activity than MMC and UCN-01 alone (P < 0.01). This synergistic antitumor effect was also confirmed in two other solid tumor cell lines, i.e. human xenografted colon carcinoma Co-3 and murine sarcoma 180. The same was observed in the i.v.-inoculated P388 leukemia model, in which we saw an increased lifespan of mice when UCN-01 was combined with MMC. These results suggests the feasibility of using UCN-01 in clinical oncology, especially in combination with alkylating agents such as MMC. In addition, this combination therapy might be a novel chemotherapeutic approach to MMC-insensitive tumors in clinical trials.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies have shown that UCN-01 abrogates Chk1-dependent cellular responses and sensitizes cancer cells to several DNA damaging agents, including mitomycin C (Akinaga et al., 1993), cisplatin (Bunch and Eastman, 1996), camptothecin (Shao et al., 1997), and 5-fluorouracil (Hsueh et al., 1998).”
From ATR–Chk1 Pathway Inhibition Promotes Apoptosis after UV Treatment in Primary Human Keratinocytes: Potential Basis for the UV Protective Effects of Caffeine (2009) · cites this paper as Akinaga et al., 1993
Citations
Cites
Hidaka, H., Inagaki, M., Kawamoto, S., & Sasaki, Y. (1984) · Biochemistry · doi:10.1021/bi00316a032 · Cited by 2,687
Staurosporine, a potent inhibitor of phospholipidCa++dependent protein kinase
Tamaoki, T., Nomoto, H., Takahashi, I., Kato, Y., Morimoto, M., & Tomita, F. (1986) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(86)90008-2 · Cited by 2,452
Giard, D. J., Aaronson, S. A., Todaro, G. J., Arnstein, P., Kersey, J. H., Dosik, H., & Parks, W. P. (1973) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/51.5.1417 · Cited by 2,289
Berenbaum, M. C. (1989) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00026-2 · Cited by 1,414
Kase, H., Iwahashi, K., Nakanishi, S., Matsuda, Y., Yamada, K., Takahashi, M., Murakata, C., Sato, A., & Kaneko, M. (1987) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(87)90293-2 · Cited by 938
Isolation and Structure of a Covalent Cross-Link Adduct Between Mitomycin C and DNA
Tomasz, M., Lipman, R., Chowdary, D., Pawlak, J., Verdine, G. L., & Nakanishi, K. (1987) · Science · doi:10.1126/science.3103215 · Cited by 452
Phorbol esters induce multidrug resistance in human breast cancer cells.
Fine, R. L., Patel, J., & Chabner, B. A. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.2.582 · Cited by 238
Akinaga, S., Gomi, K., Morimoto, M., Tamaoki, T., & Okabe, M. (1991) · PubMed · Cited by 189
Self-citationTAKAHASHI, I., SAITOH, Y., YOSHIDA, M., SANO, H., NAKANO, H., MORIMOTO, M., & TAMAOKI, T. (1989) · The Journal of Antibiotics · doi:10.7164/antibiotics.42.571 · Cited by 155
Yu, G., Ahmad, S., Aquino, A., Fairchild, C. R., Trepel, J. B., Ohno, S., Suzuki, K., Tsuruo, T., Cowan, K. H., & Glazer, R. I. (1991) · Cancer Communications · doi:10.3727/095535491820873263 · Cited by 143
Research works printed but not linked: 2
- Bush JA, Long BH, Catino JJ, Brander WT, Tomita K (1987) Production and biological activities of rebeccmycin, a novel antitumor agent. J Antibiot 40: 666
- Geran RI, Greenberg NH, MacDonald MM, Schumacher AM, Abbot BJ (1972) Protocols for screening chemical agents and natural products against animal tumors and other biological activities. Cancer Chemother Rep 3: 1
Cited by
Items 101–118 of 118
Antitumor Alkaloids in Clinical Use or in Clinical Trials
Cuendet, M., & Pezzuto, J. M. (2007) · Wiley eBooks · doi:10.1002/9783527621071.ch2 · Cited by 6
Clinical Trials in Cancer and Pharmacogenomics: A Critical Evaluation
Băianu, I. C. (2012) · Journal of Clinical Trials · doi:10.4172/2167-0870.1000109 · Cited by 5
Cancer Drugs and Cancer Drug Development for the New Millennium
Dancey, J. E., & Arbuck, S. G. (2000) · Springer eBooks · doi:10.1007/978-2-8178-0920-5_6 · Cited by 5
Grem, J. L., Danenberg, K. D., Kao, V., Danenberg, P. V., & Nguyen, D. (2002) · Anti-Cancer Drugs · doi:10.1097/00001813-200203000-00008 · Cited by 3
Senderowicz, A. M. (2003) · Humana Press eBooks · doi:10.1007/978-1-59259-401-6_8 · Cited by 2
Urano, M., Reynolds, R., & Begley, J. G. (1995) · Radiation Oncology Investigations · doi:10.1002/roi.2970030205 · Cited by 2
Banerji, U., Judson, I. R., & Workman, P. (2004) · Humana Press eBooks · doi:10.1007/978-1-59259-734-5_1 · Cited by 2
Potential Applications of Cell Cycle Manipulation to Clinical Response
Harris, E. E. R., Kao, G. D., Muschel, R. J., & McKenna, W. G. (1998) · Cancer treatment and research · doi:10.1007/978-1-4615-5769-2_8 · Cited by 2
Targeting CHK1 for Cancer Therapy: Rationale, Progress and Prospects
Gillespie, D. A. (2018) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-75836-7_9 · Cited by 1
Role of Cell Cycle Control and Cyclin-Dependent Kinases in Breast Cancer
Senderowicz, A. M. (2002) · Breast Disease · doi:10.3233/bd-2002-15105 · Cited by 3
New Drugs for the Treament of Chronic Lymphocytic Leukemia
Cheson, B. D., Dancey, J. E., & Murgo, A. J. (2000) · Reviews in Clinical and Experimental Hematology · doi:10.1046/j.1468-0734.2000.00011.x · Cited by 1
Kurata, N., Imabeppu, S., Nitoh, M., Kobayashi, H., Kuwabara, T., & Kobayashi, S. (2000) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357001777478 · Cited by 1
Overview of Specific Molecular Targeted Agents for Combined Modality Therapy
Saxman, S. B., & Dancey, J. E. (2003) · Humana Press eBooks · doi:10.1007/978-1-59259-325-5_17 · Cited by 1
Meijer, L., & Damiens, E. (2002) · Elsevier eBooks · doi:10.1016/b978-012476249-7/50008-4 · Cited by 2
Targeting the Phosphoinositide‐3‐kinase/Akt/Mammalian Target of Rapamycin Pathway
Granville, C. A., Memmott, R. M., Gills, J. J., & Dennis, P. A. (2006) · Wiley eBooks · doi:10.1002/9783527619665.ch38
Cyclin-Dependent Kinases and Their Small-Molecule Inhibitors in Cancer Therapy
Rao, R. N., & Patel, B. K. R. (2002) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-1-59259-153-4_8
DNA repair inhibition in anti-cancer therapeutics
Alexander, B. M., & D’Andrea, A. D. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139046947.091
Novel Agents and Modalities for the Treatment of Squamous Carcinoma of the Head and Neck
Senderowicz, A. M., Waes, C. V., Dancey, J. E., & Conley, B. A. (2003) · Elsevier eBooks · doi:10.1016/b978-012239990-9/50037-0
Metadata
- Authors
- Akinaga, S., Nomura, K., Gomi, K., & Okabe, M.
- ORCID
- Nomura, Kayo
- Venue
- Cancer Chemotherapy and Pharmacology
- Published
- 1993
- Volume
- 32
- Issue
- 3
- Pages
- 183-189
- ISSN
- 0344-5704 (ISSN-L)
- 1432-0843
- OpenAlex
- W2078730133
- Cited by
- 118
- References
- 22
- Citations by year
- 2024: 1 · 2023: 1 · 2018: 1 · 2017: 1 · 2014: 1 · 2013: 3 · 2012: 1
- FWCI
- 1.28
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Cancer Chemotherapy and Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- UCN-01, mitomycin C, protein kinase C inhibition, combination chemotherapy, synergistic antitumor effect, alkylating agents, staurosporine, K252a, tumor xenografts, P388 leukemia
- MeSH terms
- Alkaloids, Animals, Antineoplastic Combined Chemotherapy Protocols, Cell Cycle, Cell Division, Drug Synergism, Male, Mice, Inbred BALB C, Mice, Inbred DBA, Mice, Inbred Strains, Mice, Nude, Neoplasm Transplantation, Neoplasms, Experimental, Protein Kinase C, Tumor Cells, Cultured, Mitomycin, Staurosporine, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.